Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.
作者信息
Ray A, Das D S, Song Y, Richardson P, Munshi N C, Chauhan D, Anderson K C
机构信息
The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
出版信息
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.
Abstract
摘要
相似文献
1
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.靶向浆细胞样树突状细胞与T细胞、自然杀伤细胞和多发性骨髓瘤细胞相互作用中的PD1-PDL1免疫检查点。
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.
2
The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.在一项1期研究中，PD - 1抑制剂用于多发性骨髓瘤的免疫检查点阻断治疗失败。
Leukemia. 2015 Jul;29(7):1621-2. doi: 10.1038/leu.2015.104. Epub 2015 May 19.
3
Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?旁观者记忆 T 细胞与 IMiD/检查点疗法在多发性骨髓瘤中的应用：一场危险的探戈？
Front Immunol. 2021 Feb 15;12:636375. doi: 10.3389/fimmu.2021.636375. eCollection 2021.
4
Role of Immune Therapies for Myeloma.免疫疗法在骨髓瘤中的作用。
J Natl Compr Canc Netw. 2015 Nov;13(11):1440-7. doi: 10.6004/jnccn.2015.0168.
5
Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.靶向色氨酸分解代谢的犬尿氨酸途径增强多发性骨髓瘤的抗肿瘤免疫和细胞毒性。
Leukemia. 2020 Feb;34(2):567-577. doi: 10.1038/s41375-019-0558-x. Epub 2019 Aug 28.
6
Metabolic approaches to rescue antitumor Vγ9Vδ2 T-cell functions in myeloma.代谢途径挽救骨髓瘤中抗肿瘤 Vγ9Vδ2 T 细胞功能。
Front Biosci (Landmark Ed). 2020 Jan 1;25(1):69-105. doi: 10.2741/4795.
7
Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis.肝固有 NK 细胞通过 PD-1-PD-L1 轴控制肝 T 细胞的抗病毒活性。
Immunity. 2019 Feb 19;50(2):403-417.e4. doi: 10.1016/j.immuni.2018.12.024. Epub 2019 Jan 29.
8
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.骨髓瘤 B7-H1（PD-L1）与 PD-1 结合诱导的骨髓瘤耐药性。
Cancer Immunol Res. 2016 Sep 2;4(9):779-88. doi: 10.1158/2326-6066.CIR-15-0296. Epub 2016 Jul 20.
9
Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.非编码RNA与免疫检查点——作为癌症治疗手段的临床意义
FEBS J. 2017 Jul;284(13):1952-1966. doi: 10.1111/febs.14030. Epub 2017 Feb 17.
10
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.CT-011（一种抗 PD-1 抗体）阻断 PD-1 可增强自体树突状细胞/骨髓瘤融合疫苗体外诱导的 T 细胞反应。
J Immunother. 2011 Jun;34(5):409-18. doi: 10.1097/CJI.0b013e31821ca6ce.
引用本文的文献
1
Deciphering the bone marrow microenvironment's role in multiple myeloma immunotherapy resistance.解读骨髓微环境在多发性骨髓瘤免疫治疗耐药中的作用
Front Immunol. 2025 Jul 18;16:1613265. doi: 10.3389/fimmu.2025.1613265. eCollection 2025.
2
A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy.一种新型双特异性抗体CVL006，在癌症治疗中对PD-L1和VEGF的双重靶向作用优于AK112。
Antib Ther. 2025 May 22;8(3):189-196. doi: 10.1093/abt/tbaf012. eCollection 2025 Jul.
3
The Expression of Programmed Cell Death Ligand-1 and its Relationship with Infiltration, Metastasis and Prognosis in Cervical Squamous Cell Carcinoma.程序性细胞死亡配体-1在宫颈鳞状细胞癌中的表达及其与浸润、转移和预后的关系
Reprod Sci. 2025 May;32(5):1676-1684. doi: 10.1007/s43032-024-01784-5. Epub 2025 Jan 30.
4
From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma.从生物学至临床实践：多发性骨髓瘤中的骨髓微环境
J Clin Med. 2025 Jan 8;14(2):327. doi: 10.3390/jcm14020327.
5
Bispecific antibody targets and therapies in multiple myeloma.双特异性抗体在多发性骨髓瘤中的靶点和治疗方法。
Front Immunol. 2024 Oct 10;15:1424925. doi: 10.3389/fimmu.2024.1424925. eCollection 2024.
6
Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment.基于微环境疗法的进展：改变多发性骨髓瘤的治疗格局
Front Oncol. 2024 Jul 17;14:1413494. doi: 10.3389/fonc.2024.1413494. eCollection 2024.
7
Involvement of S100A6/S100A11 in T-Cell Immune Regulatory in HCC Revealed by Single Cell RNA-seq.单细胞 RNA-seq 揭示 S100A6/S100A11 在 HCC 中 T 细胞免疫调节中的作用。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241252610. doi: 10.1177/15330338241252610.
8
A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.一种新型的 CD73 小分子抑制剂触发免疫介导的多发性骨髓瘤细胞死亡。
Blood Cancer J. 2024 Apr 9;14(1):58. doi: 10.1038/s41408-024-01019-5.
9
Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications.多发性骨髓瘤中双特异性 T 细胞衔接器耐药的机制及其临床意义。
Blood Adv. 2024 Jun 11;8(11):2952-2959. doi: 10.1182/bloodadvances.2023012354.
10
Inhibitory receptors of plasmacytoid dendritic cells as possible targets for checkpoint blockade in cancer.浆细胞样树突状细胞的抑制性受体作为癌症检查点阻断治疗的潜在靶点。
Front Immunol. 2024 Mar 5;15:1360291. doi: 10.3389/fimmu.2024.1360291. eCollection 2024.
本文引用的文献
1
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.程序性死亡受体-1（PD-1）、PD-1配体与肿瘤免疫微环境的其他特征与抗PD-1治疗反应的相关性
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.
2
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.一种新型 TLR-9 激动剂 C792 抑制浆细胞样树突状细胞诱导的骨髓瘤细胞生长并增强硼替佐米的细胞毒性。
Leukemia. 2014 Aug;28(8):1716-24. doi: 10.1038/leu.2014.46. Epub 2014 Jan 30.
3
Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.抑制性分子 PD-1 作为多发性骨髓瘤免疫治疗的潜在靶点。
Leukemia. 2014 May;28(5):993-1000. doi: 10.1038/leu.2013.310. Epub 2013 Oct 23.
4
New checkpoint inhibitors ride the immunotherapy tsunami.新型检查点抑制剂搭乘免疫疗法的浪潮。
Nat Rev Drug Discov. 2013 Jul;12(7):489-92. doi: 10.1038/nrd4066.
5
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.自体干细胞移植后用树突细胞/肿瘤融合细胞进行疫苗接种可诱导多发性骨髓瘤患者产生免疫和临床应答。
Clin Cancer Res. 2013 Jul 1;19(13):3640-8. doi: 10.1158/1078-0432.CCR-13-0282. Epub 2013 May 17.
6
Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.短暂性淋巴清除后程序性死亡受体-1/程序性死亡受体配体-1 阻断治疗骨髓瘤。
J Immunol. 2013 Jun 1;190(11):5620-8. doi: 10.4049/jimmunol.1202005. Epub 2013 Apr 24.
7
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.骨髓基质细胞诱导骨髓瘤细胞表达 B7-H1，从而在多发性骨髓瘤中产生侵袭性特征。
Leukemia. 2013 Feb;27(2):464-72. doi: 10.1038/leu.2012.213. Epub 2012 Jul 25.
8
Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.PD-1 对 Akt 和 Ras 通路的选择性作用调节细胞周期的分子成分并抑制 T 细胞增殖。
Sci Signal. 2012 Jun 26;5(230):ra46. doi: 10.1126/scisignal.2002796.
9
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.第 39 届 David A. Karnofsky 讲座：多发性骨髓瘤靶向治疗的从基础到临床转化。
J Clin Oncol. 2012 Feb 1;30(4):445-52. doi: 10.1200/JCO.2011.37.8919. Epub 2012 Jan 3.
10
Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.多发性骨髓瘤的免疫抑制作用被 PD-L1 阻断克服。
Biol Blood Marrow Transplant. 2011 Aug;17(8):1133-45. doi: 10.1016/j.bbmt.2011.03.011. Epub 2011 Apr 12.
Zotero 插件